Intervention in Mothers and Newborns to Reduce Maternal and Perinatal Mortality in 3 Provinces in South Africa Using a Quality Improvement Approach: Protocol for a Mixed Method Type 2 Hybrid Evaluation.
HIV
antenatal
child
health systems
maternal
mixed methods evaluation
postnatal
quality improvement
Journal
JMIR research protocols
ISSN: 1929-0748
Titre abrégé: JMIR Res Protoc
Pays: Canada
ID NLM: 101599504
Informations de publication
Date de publication:
05 Jun 2023
05 Jun 2023
Historique:
received:
19
08
2022
accepted:
11
03
2023
revised:
22
02
2023
medline:
1
4
2023
pubmed:
1
4
2023
entrez:
31
3
2023
Statut:
epublish
Résumé
The COVID-19 pandemic undermined gains in reducing maternal and perinatal mortality in South Africa. The Mphatlalatsane Initiative is a health system intervention to reduce mortality and morbidity in women and newborns to desired levels. Our evaluation aims to determine the effect of various exposures, including the COVID-19 pandemic, and a system-level, complex, patient-centered quality improvement (QI) intervention (the Mphatlalatsane Initiative) on maternal and neonatal health services at 21 selected South African facilities. The objectives are to determine whether Mphatlalatsane reduces the institutional maternal mortality ratio, neonatal mortality rate, and stillbirth rate (objective 1) and improves patients' experiences (objective 2) and quality of care (objective 3). Objective 4 assesses the contextual and implementation process factors, including the COVID-19 pandemic, that shape Mphatlalatsane uptake and variation. This study is an implementation science type 2 hybrid effectiveness, controlled before-and-after design with quantitative and qualitative components. The Mphatlalatsane intervention commenced at the end of 2019. For objective 1, intervention and control facility-level data from the District Health Information System are compared for changes in institutional maternal and neonatal mortality and stillbirth rates and associations with QI, the COVID-19 pandemic, and both. This first analysis includes data from 18 facilities, regardless of their allocation to intervention or comparison, to obtain a general idea of the effect of the COVID-19 pandemic. For objectives 2 to 3, data collectors abstract data from maternal and neonatal records, interview participants, and conduct neonatal facility assessments. For objective 4, interviews, program documentation, surveys, and observations are used to assess how contextual factors at the macro-, meso-, and microlevels explain variation in intervention uptake and outcome. The intervention dose is measured at the microlevel only in the intervention facilities. The study assesses the Mphatlalatsane Initiative from 2020 to 2022. From preliminary analysis, across the 3 provinces, maternal and neonatal deaths increased during the COVID-19 pandemic, whereas stillbirths remained unchanged. Maternal satisfaction with quality of care was >90%. The COVID-19 pandemic severely disrupted the QI teams functioning. However, the QI teams regained their pre-COVID-19 momentum by adapting the QI model, with advisers providing mentoring and support. Variation in adoption at the mesolevel was related to stable and motivated leadership (particularly at the facility level), poor integration into routine processes, and buy-in from senior district managers who were affected by competing priorities. Varying referral and specialist outreach systems, staff availability and development, and service delivery infrastructure are plausible factors in variable outcomes. Few evaluations rigorously evaluated the effect of health system interventions on improving health services and outcomes. Results will inform the scaling up of successful intervention components and strategies to mitigate the effects of the COVID-19 pandemic or similar emerging epidemics on maternal and neonatal mortality. DERR1-10.2196/42041.
Sections du résumé
BACKGROUND
BACKGROUND
The COVID-19 pandemic undermined gains in reducing maternal and perinatal mortality in South Africa. The Mphatlalatsane Initiative is a health system intervention to reduce mortality and morbidity in women and newborns to desired levels.
OBJECTIVE
OBJECTIVE
Our evaluation aims to determine the effect of various exposures, including the COVID-19 pandemic, and a system-level, complex, patient-centered quality improvement (QI) intervention (the Mphatlalatsane Initiative) on maternal and neonatal health services at 21 selected South African facilities. The objectives are to determine whether Mphatlalatsane reduces the institutional maternal mortality ratio, neonatal mortality rate, and stillbirth rate (objective 1) and improves patients' experiences (objective 2) and quality of care (objective 3). Objective 4 assesses the contextual and implementation process factors, including the COVID-19 pandemic, that shape Mphatlalatsane uptake and variation.
METHODS
METHODS
This study is an implementation science type 2 hybrid effectiveness, controlled before-and-after design with quantitative and qualitative components. The Mphatlalatsane intervention commenced at the end of 2019. For objective 1, intervention and control facility-level data from the District Health Information System are compared for changes in institutional maternal and neonatal mortality and stillbirth rates and associations with QI, the COVID-19 pandemic, and both. This first analysis includes data from 18 facilities, regardless of their allocation to intervention or comparison, to obtain a general idea of the effect of the COVID-19 pandemic. For objectives 2 to 3, data collectors abstract data from maternal and neonatal records, interview participants, and conduct neonatal facility assessments. For objective 4, interviews, program documentation, surveys, and observations are used to assess how contextual factors at the macro-, meso-, and microlevels explain variation in intervention uptake and outcome. The intervention dose is measured at the microlevel only in the intervention facilities. The study assesses the Mphatlalatsane Initiative from 2020 to 2022.
RESULTS
RESULTS
From preliminary analysis, across the 3 provinces, maternal and neonatal deaths increased during the COVID-19 pandemic, whereas stillbirths remained unchanged. Maternal satisfaction with quality of care was >90%. The COVID-19 pandemic severely disrupted the QI teams functioning. However, the QI teams regained their pre-COVID-19 momentum by adapting the QI model, with advisers providing mentoring and support. Variation in adoption at the mesolevel was related to stable and motivated leadership (particularly at the facility level), poor integration into routine processes, and buy-in from senior district managers who were affected by competing priorities. Varying referral and specialist outreach systems, staff availability and development, and service delivery infrastructure are plausible factors in variable outcomes.
CONCLUSIONS
CONCLUSIONS
Few evaluations rigorously evaluated the effect of health system interventions on improving health services and outcomes. Results will inform the scaling up of successful intervention components and strategies to mitigate the effects of the COVID-19 pandemic or similar emerging epidemics on maternal and neonatal mortality.
INTERNATIONAL REGISTERED REPORT IDENTIFIER (IRRID)
UNASSIGNED
DERR1-10.2196/42041.
Identifiants
pubmed: 37000902
pii: v12i1e42041
doi: 10.2196/42041
pmc: PMC10280336
doi:
Types de publication
Journal Article
Langues
eng
Pagination
e42041Informations de copyright
©Terusha Chetty, Yages Singh, Willem Odendaal, Solange Mianda, Nada Abdelatif, Samuel Manda, Helen Schneider, Ameena Goga. Originally published in JMIR Research Protocols (https://www.researchprotocols.org), 05.06.2023.
Références
BJOG. 2015 Jul;122(8):1045-9
pubmed: 25929823
Bull World Health Organ. 2017 Jan 1;95(1):76-78
pubmed: 28053367
Int Health. 2013 Sep;5(3):180-95
pubmed: 24030269
CJEM. 2020 Jul;22(4):422-425
pubmed: 32356698
Int J Qual Health Care. 2021 Mar 5;33(1):
pubmed: 32400860
Front Glob Womens Health. 2020 Sep 25;1:564560
pubmed: 34816152
BMJ. 2013 Nov 20;347:f6753
pubmed: 24259324
Int J Qual Health Care. 2009 Jun;21(3):153-9
pubmed: 19383716
BMJ. 2020 Sep 1;370:m3320
pubmed: 32873575
S Afr Med J. 2021 Apr 12;111(6):567-569
pubmed: 34382568
Med Care Res Rev. 2016 Apr;73(2):227-46
pubmed: 26330005
J Acquir Immune Defic Syndr. 2017 Jun 1;75 Suppl 2:S156-S164
pubmed: 28498185
Health Policy Plan. 2019 Jul 1;34(6):430-439
pubmed: 31280321
Glob Health Sci Pract. 2022 Oct 31;10(5):
pubmed: 36316142
BMC Health Serv Res. 2020 Jun 8;20(1):522
pubmed: 32513236
PLoS Med. 2020 Oct 7;17(10):e1003150
pubmed: 33027246
BMC Pediatr. 2019 Jan 24;19(1):29
pubmed: 30678646
J Eval Clin Pract. 2004 Aug;10(3):387-98
pubmed: 15304139
S Afr Med J. 2021 May 17;111(8):714-719
pubmed: 35227349
BMC Pregnancy Childbirth. 2015 Apr 18;15:97
pubmed: 25928085
Bull World Health Organ. 2000;78(5):614-20
pubmed: 10859855
Gates Open Res. 2017 Nov 6;1:1
pubmed: 29355215
Int J Qual Health Care. 2021 Mar 5;33(1):
pubmed: 32400870